Are there other TREM2-targeting Alzheimer’s treatments still in development?

Drugmakers are developing the next-generation TREM2 antibodies and pills. Novartis’ VHB937 is the furthest along, with a Phase 2 trial set to finish in 2030. Vigil Neuroscience’s VG-3927, which was acquired by Sanofi, is an experimental pill that targets TREM2.